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List of non-standard abbreviations: 
 
APV, amprenavir; ATZ, atazanavir; CHO, Chinese hamster ovary; Cl, clearance; 
DMEM, Dulbecco’s modified eagle medium; DRV, darunavir; FBS, fetal bovine serum; 
ES, estrone-3-sulfate; HEPES, 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid; 
HIV, Human immunodeficiency virus; IDV, indinavir; LPV, lopinavir; NLV, nelfinavir; 
OATP/Oatp, Organic Anion Transporting Polypeptide (Human/Rat); OCT/Oct, Organic 
Cation Transporter (Human/Rat); PI, protease inhibitors; PBS, phosphate buffered saline; 
RAF, relative activity factor; RTV, ritonavir; SLC, Solute-linked carrier; SQV, 
saquinavir.  
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ABSTRACT 
The aim of this work was to explore the contribution of the Organic Anion Transporting 
Polypeptide-1B (OATP1B) drug transporters in the hepatic clearance (Cl) of all marketed 
HIV protease inhibitors (PI) in humans. HIV PI uptake rates in OATP1B1/1B3-
transfected CHO cells were converted to uptake Cl values in human hepatocytes a 
relative activity factor, which was determined by comparing uptake of known substrates 
between OATP1B1/3-transfected cells and human hepatocytes. Metabolic Cl values were 
determined in human liver microsomes. In vivo hepatic Cl values were calculated either 
by combining drug uptake and metabolism or based on one of these individual Cl 
processes and compared with published in vivo hepatic Cl values. Excellent in vitro-in 
vivo correlation (R2 = 0.85) was observed when only uptake Cl values were used, but not 
when only metabolic Cl was used (R2 = 0.40). The correlation did not improve when both 
processes were taken into account (R2 = 0.85). PBPK models confirmed the remarkable 
sensitivity of predicted exposure to hepatic drug uptake, indicating a key role for 
OATP1B1/3 in hepatic disposition of several HIV PI in man. This may contribute to the 
inter-individual variability in systemic and hepatic exposure to these drugs in the clinic.   
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INTRODUCTION 
Over the last decades, hepatic uptake transporters have been recognized to play a 
determining role in the hepatic disposition of many endogenous and exogenous 
compounds. In particular, members of the organic anion transporting polypeptide family 
(OATP; SLCO gene family) influence the hepatic Cl of many drugs. The most important 
members of the OATP family in the basolateral membrane of the hepatocyte are the 
hOATP1B1 (SLCO1B1) and hOATP1B3 (SLCO1B3) isoforms.1 Genetic polymorphism 
as well as inhibition or induction of OATP activity can lead to altered plasma 
concentrations and clinically important drug-drug interactions.2–4 
HIV PI represent an important class of therapeutic agents in the currently recommended 
treatment (Highly Active Antiretroviral Therapy; HAART) of HIV infection. Among the 
HIV PI that have been approved, lopinavir, atazanavir, darunavir and fosamprenavir are 
most frequently prescribed.5,6 HIV PI are extensively metabolized by CYP3A enzymes 7,8 
and their biliary excretion is mediated by the efflux transporters P-gp (ABCB1) and 
MRP2 (ABCC2).8,9 In addition, it has been shown that some HIV PI (or their metabolites) 
are excreted via the feces for more than 75 %.8 This illustrates that hepatic elimination is 
much more important than renal elimination for these drugs. 
Based on experiments with clinically relevant concentrations of nelfinavir, ritonavir and 
saquinavir in suspended rat hepatocytes, Parker and Houston reported that hepatic uptake 
rather than metabolism is the rate-limiting factor in the hepatic disposition of these 
compounds.10 Moreover, in addition to a carrier-mediated process, passive 
transmembrane permeation significantly contributed to the hepatic uptake of saquinavir 
and ritonavir.11 In general, previous results imply that a carrier-mediated process is 
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involved in the hepatic uptake of HIV PI. It follows that the ‘interplay’ between transport 
and metabolism has to be considered for these compounds.12,13 
Several studies have illustrated that HIV PI inhibit the in vitro cellular uptake of 
OATP1B probe substrates like estradiol-17β-D-glucuronide, CGamF and sodium 
fluorescein.14–17 Moreover, it has been suggested that inhibition of these membrane 
transporters contributes to clinically important antiretroviral drug-drug interactions, for 
example with cerivastatin and atorvastatin.18 While these examples certainly illustrate the 
clinical relevance of OATP modulation by HIV PI, the concept of meaningful OATP-
mediated transport of HIV PI remains controversial. Current evidence in this respect 
includes OATP1A2-mediated transport of saquinavir in HepG2 cells.19 Consistently, 
Hartkoorn et al. showed that saquinavir, darunavir and lopinavir have affinity for both 
OATP1A2 and OATP1B1 and that saquinavir is also transported by OATP1B3.20 
Furthermore, it has been shown that the single nucleotide polymorphism 521T>C in 
SLCO1B1 is associated with significantly increased plasma concentrations of 
lopinavir.20,21 In contrast, a recent publication showed that the hepatic uptake of 
nelfinavir, lopinavir and ritonavir is primarily mediated by passive diffusion in sandwich-
cultured human hepatocytes.22 Additionally, they suggested an unidentified sinusoidal 
uptake transporter for amprenavir. These conflicting findings highlight the need for 
further exploration of the exact role of transporter-mediated hepatic uptake of HIV PI in 
their disposition profiles. Therefore, this study aimed to investigate the contribution of 
hepatic uptake for all marketed HIV PI in one study under equal conditions. To achieve 
this goal, in vitro data for uptake and/or metabolism were extrapolated to in vivo hepatic 
Cl values and retrospectively compared with published non-renal Cl values. 
7"
"
MATERIALS AND METHODS 
Chemicals. Ritonavir, indinavir sulfate, saquinavir mesylate, nelfinavir mesylate were 
obtained from Hetero Drugs Limited (Hyderabad, India). Amprenavir was kindly donated 
by GlaxoSmithKline (Middlesex, UK). Atazanavir was provided by Bristol-Myers Squibb 
(New Brunswick, NJ) and darunavir, lopinavir and tipranavir were obtained through the 
NIH AIDS Reagent Program. Dulbecco’s modified eagle medium (DMEM), Hanks’ 
balanced salt solution (HBSS), L-glutamine, fetal bovine serum (FBS), penicillin-
streptomycin mixture (contains 10,000 IU potassium penicillin and 10,000 µg 
streptomycin sulfate per ml in 0.85% saline) and Trypsin EDTA were purchased from 
Lonza SPRL (Verviers, Belgium). Geneticin G418 was purchased from Invitrogen 
(Paisley, UK). HEPES [4-(2- hydroxyethyl)-1-piperazine-ethanesulfonic acid] was 
purchased from MP Biochemical (Illkirch, France). Triton X-100, bovine serum albumin, 
sodium fluorescein, L-proline and sodium butyrate were purchased from Sigma-Aldrich 
(Schnelldorf, Germany). For uptake experiments with suspended human hepatocytes, 
cryopreserved human hepatocytes were re-suspended in Krebs-Henseleit Buffer (NaCl 
130 mM, KCl  5.17 mM, CaCl2 1.2 mM, MgCl2 1.2 mM, HEPES 12.5 mM, Glucose 11.1 
mM, Na-pyruvate 5 mM; pH 7.4). 
Culture of OATP-transfected CHO cells. Wild-type and OATP1B1- and OATP1B3-
transfected CHO cells were cultured at passage 45 to 65, as described previously.15 CHO 
cells were grown in 75 cm2 T-Flasks in DMEM containing 1 g/1 D-glucose, 1 mM L-
glutamine, 25 mM HEPES and 110 mg/l sodium pyruvate, supplemented with 10 % FBS, 
50 µg/ml L-proline, 100 IU/ml penicillin, 100 µg/ml streptomycin. The culture media of 
the transfected cell lines additionally contained 500 µg/ml geneticin. Cells were incubated 
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at 5% CO2 and 37°C. For uptake experiments, wild-type CHO cells were seeded in 12-
well cell culture plates (Greiner-Bio-One, Wemmel, Belgium) at a density of 20,000 
cells/well while CHO-transfected cells were seeded at a density of 25,000 cells/well. 
Culture medium was replaced every other day and uptake experiments were performed on 
day 4-5 after seeding when cells were reaching confluency. One day before the 
experiment, both wild-type and transfected cells were additionally treated with 5 mM 
sodium butyrate to induce gene expression.  
Uptake studies in transfected CHO cells. Uptake experiments in transfected CHO cells 
were performed as described previously.15 Briefly, cells were washed twice with 1 
ml/well pre-warmed uptake buffer (HBSS with 10 mM HEPES, pH 7.4) and pre-
incubated for 5 min at 37 °C. After the pre-incubation, uptake buffer was aspirated and 1 
ml/well of uptake buffer, containing the desired substrate concentration was added. Cells 
were incubated for 30 s at one clinically relevant test concentration, corresponding to the 
maximum in vivo unbound plasma concentrations (see Table 1). Consequently, medium 
was quickly aspirated and cells were rinsed three times with ice-cold uptake buffer. Cells 
were lysed with 0.3 ml/well of a 70/30 methanol/water mixture (or 0.5 % Triton X in PBS 
for CGamF and estrone-3-sulfate) and placed on a plate shaker for 30 min at room 
temperature. Cell lysates were transferred to a 1.5 ml microcentrifuge tube. Samples were 
stored at -20°C until analysis. For estrone-3-sulfate, a 200 µl sample was transferred to a 
scintillation vial containing 2 ml of scintillation cocktail and radioactivity was quantified 
using liquid scintillation spectrometry (Wallac 1410, Finland). For CGamF, fluorescence 
was measured using fluorescence spectroscopy (excitation/emission wavelength; 494/520 
nm) in a Tecan Infinite M200 plate reader (Tecan Benelux, Mechelen, Belgium). Mean 
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protein content/well was determined by measuring protein content of three wells for each 
batch of CHO cells using a BCA Protein assay kit (Pierce Chemical, Rockford, IL).  
Uptake studies in cryopreserved human hepatocytes. Cryopreserved human 
hepatocytes were provided by Life Technologies. (Invitrogen, Durham, NC). Uptake 
experiments in human hepatocytes were performed as described previously.23 After 
thawing the hepatocytes at 37°C, cells were re-suspended in thawing medium (consisting 
of DMEM, 10 % (v/v) FBS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml 
insulin and 1 µM dexamethasone) and centrifuged at 168 g for 20 min. To wash the cells, 
the pellet was re-suspended in 15 ml of thawing medium and centrifuged at 50 g for 3 
min. Subsequently, hepatocytes were re-suspended in uptake buffer and cell viability and 
yield were determined with the Trypan blue method. The cell suspension was further 
diluted with uptake buffer to a cell density of 2 million cells/ml (double-concentrated cell 
suspension) and kept on ice until the start of the uptake experiments. Before the 
incubation, the double-concentrated cell suspension (500 µl) was pre-incubated for 5 min 
at 37 °C. Subsequently, 500 µl of a pre-warmed double-concentrated CGamF solution 
(20 µM) was added to initiate the incubation. To determine the non-saturable uptake 
component, experiments were also conducted at 4°C. After an incubation period of 90 s, 
triplicate 200 µl aliquots of the suspension were transferred to 1.5 ml ice-cold 
microcentrifuge tubes, containing 700 µl of an oil layer (silicone / mineral oil mixture; 
density, 1.015) above 300 µl of 8 % NaCl solution. Subsequently, the tubes were 
immediately centrifuged for 3 min at 16,000 g using a tabletop centrifuge (Eppendorf 
5415 C, Hamburg, Germany). After freezing microcentrifuge tubes in dry ice, the tube 
bottoms were cut and the contents solubilized in 300 µl 0.5% Triton X (in PBS). CGamF 
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concentration was measured by fluorescence spectroscopy (ex 494 nm; em 520 nm) in a 
Tecan Infinite M200 plate reader (Tecan Benelux, Mechelen, Belgium). Uptake rates 
were normalized for the cell density during the incubation and expressed as 
pmol/min/million cells. 
In vitro metabolism studies in pooled human liver microsomes.  Pooled human liver 
microsomes (45 donors) were provided by Kaly-Cell (Plobsheim, France). Drug 
depletion experiments were performed in a total volume of 400 µl in 48-well culture 
plates (Greiner-Bio-One, Wemmel, Belgium) placed in a shaking incubator (350 rpm, 
37°C). Microsomes were gently thawed at 37°C and diluted to a 4-fold concentrated 
protein concentration in microsomal incubation buffer (consisting of 3 mM MgCl2, 100 
mM sodium phosphate buffer, pH 7.4). A double-concentrated substrate solution (200 µl) 
was pre-incubated with a 4 fold-concentrated suspension of human liver microsomes 
(100 µl) for 10 min. To initiate the depletion experiment, 100 µl of a pre-warmed 
solution of NADPH (4 mM) and glucose-6-phosphate (12 mM) was added. Samples (75 
µl) were taken at different time points (0, 10, 20 and 30 min) and were added to an equal 
volume of ice-cold acetonitrile (containing the internal standard) to terminate the 
reaction. Samples were stored at -20°C until analysis.  
Determination of unbound fraction in liver microsomes. The fraction unbound in 
microsomal medium fumic was determined by equilibrium dialysis performed with a 
HTDialysis apparatus (HTDialysis LLC, Gales Ferry, CT) and a dialysis membrane with 
a 12-14 kDa MW cutoff. Drug solutions (10 µM) were prepared in incubation medium 
containing 0.25 mg liver microsomal protein/ml and equilibrium dialysis was performed 
against protein-free microsomal incubation buffer in a shaking device (175 rpm) at 37°C. 
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Samples were taken from both sides of the well after 4 h and stored at -20°C until 
analysis. The fraction unbound was calculated as the ratio of drug concentration in the 
protein-free medium over that in the protein-containing medium. 
LC-MS/MS analysis. Samples from experiments with transfected cells, liver microsomes 
and hepatocytes were vortexed and centrifuged at 10,000 g for 10 min. The supernatant 
was transferred to high performance liquid chromatography vials and analyzed by ultra-
performance liquid chromatography tandem mass spectrometry. A Thermo Scientific (San 
Jose, CA) Accela pump, Accela autosampler, and a Waters Acquity CSH D18 column 
(3.0 x 50 mm, 1.7µm) with a VanGuard pre-column were used for all chromatographic 
separations. The mobile phase initially consisted of 95/5, v/v (0.5 mM ammonium acetate 
buffer, pH 3.5 / methanol), which gradually decreased to 5/95, v/v (0.5 mM ammonium 
acetate buffer, pH 3.5 / methanol) over 2 min. After 1 min, the initial condition of 95/5, 
v/v (0.5 mM ammonium acetate buffer, pH 3.5 / methanol) was again obtained (over 10 s) 
and maintained for 1 min. The flow rate was 400 µl/min. The column oven and 
autosampler temperature were set at 30° and 15 °C, respectively. Tandem mass 
spectrometry detection was carried out using a Thermo TSQ Quantum Access (Thermo 
Fisher Scientific, San Jose, CA) with an Ion Max H-ESI source in positive ionization 
mode. Transitions monitored and automatically optimized electric parameters are listed in 
Table 2. For all analytical methods, the intra- and interday precision (n = 6) of standards 
with low (5 nM), medium (50 nM) and high (500 nM) concentration was below 15 %, 10 
% and 10 %, respectively. Both intra- and interday bias of the same standards was lower 
than 10 %.    
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Kinetic analysis. Net uptake values were obtained by subtracting uptake in wild-type 
CHO cells and uptake in hepatocytes at 4°C from total uptake at 37°C in transfected cells 
and hepatocytes, respectively. Subsequently, uptake Cl values (µl/min/mg protein or 
µl/min/million cells) were calculated by dividing the net uptake value by the 
corresponding substrate concentration.  
Similarly, passive uptake Cl values were calculated by dividing uptake in wild-type CHO 
cells by the corresponding substrate concentration. 
For drug depletion experiments, the log of the drug concentration was plotted in function 
of time and the elimination constant was calculated by fitting a single exponential decay. 
This elimination constant was used to calculate the half-life of the metabolic turn-over, 
which was further converted to the intrinsic metabolic Cl according to following 
equation:24 
!"!"# = !.!"#!! ! × !"#$%&'!("!!"#$%&!"!!"#$%&'   Eq.1 
These Cl values, determined for different substrate concentrations, were further converted 
to the metabolic rates by multiplying them with the corresponding substrate 
concentrations. Metabolic rate data in function of concentration followed Michaelis-
Menten kinetics and non-linear regression in R for Windows (v. 2.15, R Foundation, 
Vienna, Austria) was used to determine the kinetic parameters Km and Vmax. The intrinsic 
metabolic Cl (Clint,met ) was calculated as follows: !"!"#,!"# = !!"#!×!!!!!!(!!,!"#×!!)  Eq.2 
 
Estimation of uptake Cl of HIV PI in human hepatocytes. The methodology based on 
relative activity factor (RAF) to estimate the contribution of each transporter to the total 
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hepatic uptake was introduced by Kouzuki et al. and applied to estimate the contribution 
of OATP1B1 and OATP1B3 to the hepatic uptake of fexofenadine, pitavastatin and 
rosuvastatin in humans.25–28 Following this method, we derived the hepatic Cl of all HIV 
PI in human hepatocytes. With an OATP1B1/OATP1B3 uptake ratio of 9.14 for estrone-
3-sulfate and 0.14 for CGamF, these probe substrates have been shown to be strongly 
preferred substrates of OATP1B1 and OATP1B3, respectively.15 The ratio of the uptake 
Cl of these reference compounds in human hepatocytes to that in transfected CHO cells is 
defined as the relative activity factor (RAF) and was calculated as described in following 
equations: !"#!"#$!!! = !"Hep,%%ES!!"OATP1B1,((ES Eq. 4 !"#!"#!!!! = !"!"#,!"#$%!!"!"#$!!!,!"#$% Eq. 5 
Subsequently, the uptake Cl of all HIV PI in human hepatocytes Clint,upt was calculated as 
the sum of the uptake Cl of HIV PI in transfected CHO cells multiplied by the 
corresponding RAF values, as described by following equation: !"!"#,!"# = !"!"#$!!!,!"#!!"!×!"#!"#$!!!! + !"!"#$!!!,!"#!!"!×!"#!"#$!!!! Eq. 6 
The passive uptake Cl of HIV PI in human hepatocytes was estimated based on the 
passive diffusion measured in wild-type CHO cells by correcting for the different cell 
surface area between human hepatocytes (1093 µm2) and CHO cells (615 µm2).29,30 To"
anticipate" the" effects" of" potential" differences" in" passive" diffusion" in" CHO" cells" and" human"
hepatocytes," we" simulated" the" effect" of passive uptake Cl on the relationship between 
reported and calculated hepatic Cl of HIV PI. 
In vitro – in vivo extrapolation of hepatic Cl. To evaluate the rate-limiting step in the 
overall hepatic elimination of HIV PI, the reported in vivo hepatic Cl of HIV PI was 
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predicted based on uptake data only, metabolism data only or a combination of both. 
Therefore, the determined in vitro intrinsic uptake or metabolic Cl values were first scaled 
to the intrinsic in vivo Cl by following reported scaling factors; hepatocytes per gram liver 
(HPGL) of 117.5, microsomal protein per gram liver (MPPGL) of 39.8 and a liver weight 
of 1648 g. Based on the well stirred model, these intrinsic in vivo Cl values were 
converted to hepatic Cl values according to following equations; !!!!!!!!!!!!!!!!!"!"#,!"# = !!!×!!×(!"!"#,!"#!!!"!"##$%&)!!!!!!×(!"!"#,!"#!!"!"##$%&)                Eq. 7 
              !"!"#,!"# = !!!×!!×!"!"#,!"#!!!!!!×!"!"#,!"#!!!!!!!!!                     Eq. 8 
with Qh the in vivo hepatic plasma flow (900 ml/min) and fu the reported unbound fraction 
in plasma (Table 1). To predict hepatic plasma Cl based on the combination of both 
uptake and metabolism data, following equation was used;31 !!!!!!!!!!!!!!!!!!!!!!"!"# = !!!×!!×!!"!"#,!"#×(!"!"#,!"#!!!"!"##$%&)!!× !"!"#,!"#!!"!"##$%& !((!"!"#,!"#!!!"!"##$%&)×!!×!"!"#,!!")          Eq. 9 
 
PBPK modelling for amprenavir, atazanavir and darunavir. Plasma concentration 
time profiles for three selected HIV protease  inhibitors (amprenavir, darunavir, 
atazanavir) were predicted with the Simcyp simulator v14.1 (Certara, Princeton NJ). The 
relevant physicochemical data along with previously reported in vitro data on these 
model PI as well as in vitro hepatic disposition data generated in the present study are 
shown in Table 3. The distribution volume was predicted by modifying the scalar for 
tissue/plasma partition coefficients to obtain a value corresponding to the reported 
volume of distribution. A comparison was made with clinically observed systemic 
exposure profiles of these HIV PI following single oral dosing at relevant dose. Exposure 
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profiles were first predicted taking into account only hepatic enzyme kinetics (as 
determined in human liver microsomes in the present study). Subsequently, the 
permeability-limited liver model was applied by implementing values for passive 
(sinusoidal) transmembrane clearance as well as OATP1B1/3-mediated uptake clearances 
as measured in the present study. The values used for each HIV PI are also included in 
Table 3. 
 
Statistics A two-tailed Student’s t-test (analysis tool in Microsoft Excel 2010, p < 
0.05/0.01) was used to evaluate statistical differences between uptake in wild-type and 
OATP1B1/OATP1B3-transfected CHO cells. 
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RESULTS 
Time-dependent uptake of HIV PI.  
Stably-transfected OATP1B1/3 CHO cells represent a validated in vitro model to study 
the contribution of a distinct transporter isoform in the hepatic disposition of a 
compound.14,15,32 To mimic the dynamic in vivo environment in view of determining 
transport kinetics, initial uptake rates should be measured. Therefore, initial uptake 
experiments were performed as a function of time in order to determine the linear range 
in the in vitro profiles. Supplemental Figure 1 shows the time-dependent uptake of 
tipranavir (0.25 µM) and indinavir (2.5 µM) in wild-type and OATP1B1- and OATP1B3-
transfected CHO cells, demonstrating that initial uptake rates in transfected CHO cells 
decrease at incubation times longer than 30 s, while in wild-type CHO cells, linearity is 
maintained up to 90 s. Comparable profiles were obtained for other HIV PI. In further 
experiments, a 30 s incubation time was employed (which also represents the first 
practically feasible time point).  
Uptake of HIV PI in transfected CHO cells.  
A systematic comparison of the uptake of all HIV PI in OATP1B1- and OATP1B3-
transfected cells is shown in Figure 1. Cells were incubated for 30 s at one clinically 
relevant test concentration, corresponding to the maximum in vivo unbound plasma 
concentrations (see Table 1). In OATP1B1-transfected CHO cells, atazanavir and 
lopinavir showed the highest relative uptake (> 3 fold). Except for amprenavir (where the 
uptake was lower compared to wild-type cells), the uptake of other HIV PI was also 
significantly higher compared to wild-type CHO cells. In OATP1B3-transfected CHO 
cells, tipranavir showed the highest relative uptake (3-fold), whereas the uptake ratios of 
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darunavir, atazanavir, saquinavir, ritonavir and nelfinavir were comparable (1.5-2-fold). 
The uptake of lopinavir in OATP1B3-transfected cells was not significantly higher 
compared to the uptake in wild-type cells. Amprenavir showed lower uptake in both 
transfected cell lines than in wild-type CHO cells. 
Estimation of the uptake Cl of HIV PI in human hepatocytes. 
The uptake Cl of all HIV PI in human hepatocytes was estimated using the RAF 
approach, previously applied to estimate the Cl of pitavastatin, rosuvastatin and 
fexofenadine in human hepatocytes.26–28  
The ratio between the uptake Cl of reference compounds (estrone-3-sulfate for OATP1B1 
and CGamF for OATP1B3) determined in human hepatocytes and transfected cells, is 
defined as the relative activity factor (Table 4). These RAF values were used to predict 
the active uptake Cl of HIV PI in human hepatocytes (Table 5) as described in the 
materials and methods section. Calculated total uptake Cl values (as the sum of active 
and passive Cl) of HIV PI in human hepatocytes ranged from 12.1 to 383.4 
µl/min/million cells.  
Metabolic Cl of HIV PI in human liver microsomes. 
Metabolic Cl of all HIV PI was determined using the half-life approach over a range of 
concentrations (0.1 – 5 µM) in pooled human liver microsomes (0.025-0.25 mg 
protein/ml). Depletion profiles were log-linear over the time-course studied (up to 30 
min) with a minimum compound loss of 20 %. As illustrated for tipranavir in Figure 2, 
metabolic rate in function of concentration followed Michaelis-Menten type kinetics. The 
kinetic parameters Km, Vmax and Cl are summarized in Table 6 for all HIV PI. The 
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intrinsic metabolic Cl was corrected for the unbound fraction in the microsomal 
incubation medium fumic (Eq 2). 
Hepatic Cl predictions of HIV PI. 
The in vitro Cl values for hepatic uptake (Clint,upt and Clpassive) and metabolism (Clint,met) 
were scaled up and the hepatic plasma Cl was calculated based on the individual 
processes or on the combination of both uptake and metabolism according to equations 7, 
8 and 9, respectively.  
The relationship between the reported and calculated hepatic Cl of all HIV PI is shown in 
Figure 3. Based on uptake data only (Figure 3, panel A), a linear correlation (R2 = 0.85) 
between the reported and predicted in vivo Cl was found, although in vivo hepatic Cl was 
systematically under-predicted by approximately a factor 4. In contrast, a poor correlation 
(R2 = 0.40) was observed when in vitro – in vivo extrapolations were based on 
metabolism data only (Figure 3, panel B). When both uptake and metabolism processes 
were taken into account (Figure 3, panel C), the correlation between reported and 
predicted in vivo hepatic Cl was equal to that based on uptake data only (R2 = 0.85).  
The effect of the passive uptake Cl on the relationship between reported and calculated 
hepatic Cl values of HIV PI is shown in Figure 4. When the experimentally determined 
passive uptake Cl of each protease inhibitor was increased or decreased with a factor 2, a 
minimal effect on the correlation coefficient was observed. On the contrary, when passive 
uptake Cl becomes less than 40 % of the experimentally determined passive uptake Cl, a 
poor relationship is obtained between the reported and calculated hepatic Cl values of 
HIV PI. 
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Simulating the impact of modulation of transporter activity on clearance. 
To simulate the interaction potential with active hepatic uptake of HIV PI, the effect of 
inhibition and induction of the hepatic uptake on the hepatic Cl of HIV PI is represented 
in Figure 5. This simulation showed that the hepatic Cl of atazanavir, lopinavir and 
tipranavir decreased approximately by 50 % when active hepatic uptake is inhibited by 
90 %. On the contrary, a limited decrease of the hepatic Cl of other HIV PI is observed 
when active uptake was inhibited. The predicted effect of induction of transporter 
expression on the hepatic Cl of hepatocytes revealed a significant increase in the hepatic 
Cl of darunavir, atazanavir, lopinavir, ritonavir and tipranavir when hepatic uptake was 5 
times increased, whereas only a limited effect was observed for nelfinavir, saquinavir, 
indinavir and amprenavir.   
PBPK modelling for amprenavir, atazanavir and darunavir.  
Predicted" plasma" concentration" time" profiles" (Figure" 6)" based" on" PBPK" models" assuming"
perfusionLlimited" hepatic" elimination" ignore" the" possible" role" of" active" and" passive" hepatic"
uptake" transport." Under" those" conditions," plasma" concentrations" are" largely" underpredicted"
(implying" overprediction" of" hepatic" clearance)." When" permeabilityLlimited" liver" models" are"
applied," the" values" obtained" in" the" present" study" for" passive" uptake" clearance" as"well" as" for"
OATP1B1" and" OATP1B3Lmediated" uptake" can" be" implemented." This" resulted" in" a" very" good"
prediction"of" atazanavir" exposure,"whereas" some" improvement" is" observed" for" the"other" two"
HIV"protease"inhibitors. 
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DISCUSSION  
HIV PI are potent inhibitors of the hepatic transport proteins OATP1B1 and 
OATP1B3.14,16,17,33 Consistently, OATP inhibition explained the marked increase in the 
area under the plasma concentration-time curve of the OATP1B1 substrates bosentan and 
rosuvastatin, when co-administered with the combination of lopinavir and ritonavir in 
healthy volunteers.34,35 In addition to the OATP1B inhibitory potential of HIV PI, several 
studies revealed that these drugs also show affinity for OATP1B isoforms as 
substrates.19,20 Moreover, the 521T>C gene polymorphism in SLCO1B1 is significantly 
associated with higher lopinavir plasma concentrations.20 These findings raise the 
question whether hepatic OATP isoforms play a pivotal role in the hepatic uptake of HIV 
PI. The aim of this study was to further investigate the exact role of hepatic uptake 
transport in the overall hepatic Cl of HIV PI.  
The uptake of HIV PI in OATP1B-transfected CHO cells (Figure 1) confirmed that 
lopinavir, darunavir and saquinavir are substrates for OATP1B1 and that saquinavir is 
also a substrate for OATP1B3 as published by Hartkoorn et al.20 In addition, we showed 
that also other HIV PI including atazanavir, tipranavir and indinavir are transported by 
these uptake transport proteins. The relatively limited contribution of uptake transporters 
for nelfinavir and ritonavir is in agreement with a recent publication by Liu et al. in 
sandwich-cultured human hepatocytes. 22 The observation that amprenavir uptake is not 
enhanced in OATP1B-transfected cells is consistent with its relative low inhibitory 
capacity (higher Ki values) of the OATP1B probe substrates (e.g. sodium fluorescein) 
compared to other  HIV PI.14,15,17 Surprisingly, amprenavir uptake was lower in 
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transfected-CHO cells, which may explained by the action of endogenous (efflux) 
transporters in this model system. 
Suspended or sandwich-cultured human hepatocytes are routinely used to determine the 
hepatic uptake Cl of drugs or drug candidates. Nevertheless, these in vitro model systems 
are characterized by the involvement of other processes determining the overall hepatic 
Cl (e.g. metabolism and biliary excretion) and often show high inter-donor variability in 
transporter activities.23 Therefore, we estimated an average intrinsic uptake Cl of HIV PI 
in human hepatocytes based on transfected CHO cells by relying on relative activity 
factors (RAF).26–28 The RAF, the ratio between the uptake Cl values of selective 
reference compounds in human hepatocytes and transfected cells, is used to extrapolate 
the uptake Cl of test compounds determined in transfected cells to the uptake Cl in 
human hepatocytes Cl (Table 5 and 6). Experimentally determined RAF values for 
estrone-3-sulfate (0.70, OATP1B1) and CGamF (0.1, OATP1B3) are in good agreement 
with those previously published for the OATP1B1 substrate estrone-3-sulfate (0.76) and 
the OATP1B3 substrate cholecystokinin octapeptide (0.16).26 When intrinsic uptake Cl 
values were further extrapolated to the hepatic Cl with the well stirred model, a good 
correlation (R2 = 0.85) between predicted and reported and in vivo Cl values was 
observed (Figure 3, panel A). This suggests that hepatic uptake is the rate-limiting 
process in the overall Cl of HIV PI. 
To compare the relative role of hepatic uptake to that of metabolism, we also estimated 
the hepatic Cl of HIV PI based on metabolism data only. Previous research has shown 
that the in vivo hepatic Cl can accurately be estimated from in vitro data in both 
microsomes and hepatocytes.36 Nevertheless, hepatic uptake transporters have been 
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shown to modulate Cl of compounds that is predominantly mediated by metabolic 
enzymes when measured in hepatocyte systems.31 Therefore, the metabolic intrinsic Cl of 
HIV PI was measured in pooled liver microsomes (Table 6). In general, our metabolic 
data were consistent with previously published metabolic Cl values determined in human 
microsomes with a maximum 5-fold difference for darunavir.37–40 This discrepancy as 
well as other small deviations from our data may result from differences in methodology 
or the lack of correction for nonspecific binding in some studies. When intrinsic 
metabolic Cl values were extrapolated to the hepatic Cl with the well stirred model, a 
poor correlation with the reported in vivo Cl values of HIV PI (R2 = 0.40) was found 
(Figure 3, Panel B). This illustrates that even for drugs that are generally regarded as 
being extensively metabolized, hepatic uptake can still play a significant role in the 
overall hepatic Cl.  
To further investigate the interplay between hepatic uptake and metabolism, the in vitro – 
in vivo extrapolation of the hepatic Cl of HIV PI was also conducted using a model, 
incorporating both hepatic uptake and metabolic Cl values.31 Compared to the approach 
based on hepatic Cl only, no further improvement of the in vitro – in vivo correlation (R2 
= 0.85) was observed (Figure 3, Panel C), further confirming the rate-determining role of 
hepatic uptake in the overall Cl. 
Because we estimated the passive Cl of HIV PI in human hepatocytes based on the 
passive diffusion into wild-type CHO cells, we also simulated the impact of the passive 
uptake Cl value on the overall in vitro – in vivo correlations between reported and 
predicted hepatic Cl of HIV PI (Figure 4). When the experimentally determined passive 
uptake Cl of each PI was relatively increased or decreased with a factor 2, only a 
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marginal effect on the correlation coefficient was observed. This suggests that up to 2-
fold inaccuracies in passive diffusion estimates or moderate involvement of sinusoidal 
efflux transport would not substantially affect the conclusion regarding the rate-limiting 
role of hepatic uptake transporters in HIV PI disposition. In this context, it is noteworthy 
that nelfinavir has indeed been recently shown to be a substrate and inhibitor for the 
sinusoidal efflux transporter MRP4 (ABCC4).41 
To further assess the impact of OATP1B inhibition or induction, the sensitivity of overall 
Cl predictions towards alterations in active hepatic uptake Cl was evaluated for each 
individual HIV PI (Figure 5). Our simulations revealed that decreased hepatic Cl can be 
expected for lopinavir, atazanavir and tipranavir upon potent inhibition of OATP1B-
mediated transport Cl. These findings are in agreement with the increased plasma 
concentration of lopinavir in presence of the 521T>C gene polymorphism in SLCO1B1.20 
On the contrary, other HIV PI will most likely not be involved as victim drugs in drug – 
drug interactions mediated by OATP-mediated uptake inhibition. Furthermore, these data 
showed that induction of the OATP1B expression in hepatocytes may lead to an 
increased hepatic Cl of several HIV PI, contributing to variability in plasma 
concentrations of these drugs.  
Results! from" PBPK" modelling" for" three" selected" HIV" protease" inhibitors" illustrate" improved"
prediction" of" plasma" concentrations" when" hepatic" uptake" data" are" included" (Figure" 6)." The"
increase" in" predicted" plasma" concentrations" upon" switching" from" a" perfusionLlimited" to" a"
permeabilityLlimited" liver" model" is" consistent" with" hepatic" uptake" transport" being" the" rateL
limiting" step" in" hepatic" elimination" of" these"HIV" protease" inhibitors." However," the" PBPK" data"
also"illustrate"the"necessity"to"determine"other"transporterLmediated"processes"for"these"HIV"PI"
in"human"liver"(e.g."sinusoidal"efflux"transport"and"biliary"excretion)."It"should"also"be"noted"that"
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the" substantial" underprediction" of" amprenavir" exposure" may" be" due" to" autoLinhibition," as"
amprenavir" has" been" reported" to" be" both" a" competitive" and" mechanismLbased" inhibitor" of"
CYP3A4/5.42,43"However," several"attempts" to" take" this" into"account" in" the"PBPK"model"did"not"
lead"to"improved"predictions:"implementation"of"competitive"inhibition"had"limited"effect,"while"
implementation" of" mechanismLbased" inhibition" resulted" in" extremely" slow" elimination" as"
compared" to" observed" data." This" suggests" that" other" processes" are" also" involved" requiring"
further"in"vitro"investigations."""" 
In conclusion, these results illustrate that several HIV PI are transported in vitro by 
OATP1B1 and OATP1B3 isoforms in transfected cells. By combining the RAF method 
for determining active hepatic uptake Cl with estimates for passive uptake Cl, we 
revealed that hepatic uptake is the rate-limiting process in the overall hepatic Cl of 
several HIV PI. Therefore, potent inhibition or induction of transporter-mediated uptake 
of these drugs may significantly influence of plasma concentrations of some HIV PI. 
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FIGURE LEGENDS 
Supplemental Figure 1 
Time-dependent uptake of tipranavir (panel A) and indinavir (panel B) by wild-type 
(circles), OATP1B1- (squares) and OATP1B3- (triangles) transfected CHO cells. CHO 
cells were incubated with 0.25 µM TPV and 2.5 µM IDV. Points represent mean (± SD) 
of triplicate determinations.  
Figure 1 
Uptake of HIV PI by OATP1B1- (black bars) and OATP1B3- (open bars) transfected 
CHO cells Bars represent mean (± SD) uptake ratios obtained by normalizing the uptake 
in transfected cells for the uptake in wild-type CHO cells. ** p < 0.01 and * p < 0.05 
(two-tailed Student’s t-test). Uptake (30 s) was determined at one clinically relevant test 
concentration; 1 µM for amprenavir, atazanavir and tipranavir; 2.5 µM for indinavir; 0.25 
µM for lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir. 
Figure 2 
Relationship between metabolic rate and tipranavir concentration in pooled (n = 45) 
human liver microsomes. Points represent means (± SD) of triplicate incubations and the 
solid line represents the best fit to experimental data according to the Michaelis-Menten 
equation. 
Figure 3 
Relationship between the reported and calculated hepatic Cl of all HIV PI. Calculated 
hepatic Cl was predicted based on in vitro uptake Cl data only  (A), metabolic Cl data 
only (B) or a combination of both uptake and metabolic Cl data (C).  
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Figure 4 
Simulation of the effect of the passive uptake Cl on the relationship between reported and 
calculated hepatic Cl of HIV PI. The predicted correlation coefficient of the relationship 
between reported and calculated hepatic Cl is expressed in function of the passive Cl 
(expressed as a percentage of the measured passive Cl).  
Figure 5 
Simulation of the effect on the hepatic Cl when active uptake is 90 % inhibited (open 
bars) or when active uptake is 5-fold induced (grey bars) in function of control condition. 
Figure 6 
Observed (points) and predicted (lines) plasma concentration time profiles for darunavir, 
atazanavir and amprenavir. Predictions were generated based on PBPK models in the 
Simcyp simulator v.14. Left and right panels represent predictions for perfusion-limited 
and permeability-limited liver models. All other parameters were kept fixed between both 
models.
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Table 1 
Comparison of the experimental concentrations used in the present study to the reported 
maximum unbound peak plasma concentrations of HIV PI. 
Substrate 
In vitro 
concentration (µM)  
(present study) 
fu 
Unbound peak plasma 
concentrations (µM) 
(reported) 
Reference 
Amprenavir 1 0.1 1 – 3.2 44 
Atazanavir 1 0.14 0.6 – 1.3 45 
Darunavir 1 0.07 0.3 – 1.1 46,47 
Indinavir 2.5 0.35 1.7 – 4.4 48 
Lopinavir 0.25 0.02 0.3 49 
Nelfinavir 0.25 0.02 0.1 50 
Ritonavir 0.25 0.01 0.16 51 
Saquinavir 0.25 0.02 0.11 – 0.3 52 
Tipranavir 0.25 0.001 0.06 – 0.19 46 
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Table 2 
Transitions monitored, optimized parameters and retention time for LC-MS/MS analysis.  
Substrate Transition CT VT SG AG ISG CE RT (min) 
Darunavir 548.3 ! 392.3 275 300 30 5 20 12 2.7 
Atazanavir 705.4 ! 168.1 170 300 50 0 40 43 3.16 
Lopinavir 629.4 ! 155.2 170 300 50 0 40 38 3.4 
Saquinavir 671.5 ! 570.4 275 300 60 55 10 29 3.25 
Ritonavir 
 
 
 
721.3 !140.0 
721.3 !197.0 
721.3 !268.1 
721.3 !296.0 
220 
 
 
 
300 
 
 
 
60 
 
 
 
10 
 
 
 
25 
 
 
 
57 
35 
24 
16 
3.19 
 
 
 
Tipranavir 
 
603.3 ! 411.1 
603.3 ! 585.4 
280 
 
300 
 
60 
 
0 
 
10 
 
21 
14 
3.34 
 
Nelfinavir 568.3 ! 330.1 275 300 50 10 10 30 3.3 
Indinavir 614.5 ! 421.3 275 300 50 5 10 32 2.94 
Amprenavir 506.3 ! 245.2 270 300 60 2 30 17 2.68 
CT, capillary temperature; VT, vaporizing temperature; SG, sheet gas; AG, auxiliary gas; ISG, 
ion sweep gas; CE, collision energy; RT, retention time 
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Table 1 
Comparison of the experimental concentrations used in the present study to the reported 
maximum unbound peak plasma concentrations of HIV PI. 
Substrate 
In vitro 
concentration (µM)  
(present study) 
fu 
Unbound peak plasma 
concentrations (µM) 
(reported) 
Reference 
Amprenavir 1 0.1 1 – 3.2 44 
Atazanavir 1 0.14 0.6 – 1.3 45 
Darunavir 1 0.07 0.3 – 1.1 46,47 
Indinavir 2.5 0.35 1.7 – 4.4 48 
Lopinavir 0.25 0.02 0.3 49 
Nelfinavir 0.25 0.02 0.1 50 
Ritonavir 0.25 0.01 0.16 51 
Saquinavir 0.25 0.02 0.11 – 0.3 52 
Tipranavir 0.25 0.001 0.06 – 0.19 46 
"
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Table"3:"Physicochemical"parameters"and"reported"or"experimentally"determined"in#vitro"drug"
disposition"data"used"as"input"parameters"for"Simcyp"simulations."
 Amprenavir Atazanavir Darunavir 
Physicochemical parameters    
Log P 2.43 4.5 1.8 
pKa (basic) 2.39 4.42 / 1.37 2.39 
B/P 1.99 1.09 0.7 
fu 0.1 0.14 0.07 
Absorption    
passive Caco-2 Papp (10-6 cm/s) 38 25 30 
predicted Peff man (10-4 cm/s)  2.416 1.724 1.997 
predicted fugut  0.030 0.00027 0.117 
Q gut (predicted) 9.98 8.37 9.07 
Distribution    
Vd (L/kg; predicted with Method 2) 6.140 1.550 1.259 
Scalar 5.5841 0.00657 5.3671 
Elimination    
 Enzyme kinetics (CYP3A4)    
Vmax  
(pmol/min/mg microsomal protein) 
287 138 157 
Km (µM) 0.355 0.362 0.159 
fumic 0.8 0.71 0.56 
 Clrenal (L/h) 0.22 0.9 0.39 
Transport    
 Intestine    
ABCB1 (P-gp; Clint, t; µl/min) 0.18 0.18 0.42 
 Liver    
CLPD (mL/min/106 hep) 0.0855 0.0043 0.0084 
Sinus. uptake 
(µl/min/106 cells) 
 OATP1B1 
 OATP1B3 
 
 
- 
- 
 
 
6.3 
0.3 
 
 
2.87 
0.89 
 Canalicular efflux 
(µl/min/106 cells) 
 ABCB1 (P-gp)  
 
 
- 
 
 
0.401 
 
 
0.18 
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Table 4  
 
Uptake Cl of reference compounds (estrone-3-sulfate for OATP1B1 and CGamF for 
OATP1B3) in pooled human hepatocytes and OATP1B1- and OATP1B3-transfected 
CHO cells. The ratio of the uptake Cl of these reference compounds in human 
hepatocytes to that in transfected CHO cells is defined as the relative activity factor 
(RAF). 
 estrone-3-sulfate CGamF 
Clhep (µl/min/million cells) 99.123 14.8 
ClOATP1B1 (µl/min/mg protein) 141.753 (7.8)14 
ClOATP1B3 (µl/min/mg protein) (32) 14214 
RAFOATP1B1 0.70 N.D. 
RAFOATP1B3 N.D. 0.11 
N.D. not determined 
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Table 5 
Uptake Cl values of HIV PI measured in OATP1B1- and OATP1B3-transfected cells and 
predicted in human hepatocytes based on relative activity factor.  
 Uptake Cl in transfected CHO cells (µl/min/mg protein) 
Predicted uptake Cl in human 
hepatocytes 
Compound WT OATP1B1 OATP1B3  (µl/min/million cells) 
Darunavir 8.4 4.1 8.0 12.1 
Atazanavir 4.3 9.0 2.8 10.9 
Lopinavir 31.5 68.5 7.6 80.2 
Saquinavir 155.4 51.0 34.9 194.7 
Ritonavir 37.7 18.2 31.8 53.7 
Tipranavir 119.0 168.1 236.4 261.5 
Nelfinavir 285.8 113.3 174.3 383.4 
Indinavir 7.9 5.0 9.8 12.4 
Amprenavir 85.5 0 0 85.5 
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Table 6 
In vitro metabolic Cl of all HIV PI determined in pooled (n = 45) liver microsomes. 
Substrate Km  (nM)  
Vmax  
(pmol/min/mg protein) 
Clint, met 
(ml/min/mg protein) 
Clint, met / fu, mic 
(ml/min/mg protein) 
Darunavir 159 157 0.99 1.76 
Atazanavir 362 138 0.38 0.54 
Lopinavir 879 3879 4.4 4.82 
Saquinavir 288 1238 4.3 7.36 
Ritonavir 325 61.0 0.17 0.22 
Tipranavir 437 833 1.91 2.77 
Nelfinavir 340 334 0.98 7.59 
Indinavir 124 119 0.42 0.51 
Amprenavir 355 287 0.81 1.01 
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